{"id":4468,"date":"2026-01-19T17:58:42","date_gmt":"2026-01-19T14:58:42","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=4468"},"modified":"2026-01-22T11:56:29","modified_gmt":"2026-01-22T08:56:29","slug":"bilim-ve-inovasyonla-buyuyen-insanla-guclenen-bir-yolculuk","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=4468","title":{"rendered":"Bilim ve \u0130novasyonla B\u00fcy\u00fcyen, \u0130nsanla G\u00fc\u00e7lenen Bir Yolculuk"},"content":{"rendered":"\n

AbbVie T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Barlas D\u00f6ner ile \u015firketin odakland\u0131\u011f\u0131 tedavi alanlar\u0131ndan Ar-Ge \u00e7al\u0131\u015fmalar\u0131na, sosyal sorumluluk anlay\u0131\u015f\u0131ndan kurum k\u00fclt\u00fcr\u00fc ve \u0130K stratejilerine kadar uzanan kapsaml\u0131 bir s\u00f6yle\u015fi ger\u00e7ekle\u015ftirdik.<\/strong><\/p>\n\n\n\n

Biraz kendinizden ve AbbVie\u2019nin vizyonu ile odakland\u0131\u011f\u0131 tedavi alanlar\u0131ndan bahseder misiniz?<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Sa\u011fl\u0131k sekt\u00f6r\u00fcnde kariyerime 2006 y\u0131l\u0131nda ba\u015flad\u0131m. 2017 y\u0131l\u0131nda AbbVie ailesine kat\u0131ld\u0131m. T\u00fcrkiye ve yurt d\u0131\u015f\u0131nda \u00e7e\u015fitli liderlik rollerinde bulundum. Spesifik farma ve onkoloji birimlerinin y\u00f6neticili\u011finden Allergan Aesthetics T\u00fcrkiye Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc’ne, oradan da \u0130ngiltere\u2019ye uzanan bir yolculu\u011fum oldu. \u015eubat 2023\u2019ten AbbVie T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc olarak atand\u0131\u011f\u0131m Ocak 2025 tarihine kadar Allergan Aesthetics Uluslararas\u0131 Pazarlama ve Ticari Operasyonlar liderlik ekibinde Marka M\u00fckemmelli\u011fi ve Sat\u0131\u015f G\u00fcc\u00fc Etkinli\u011fi Ba\u015fkan Yard\u0131mc\u0131l\u0131\u011f\u0131 g\u00f6revini y\u00fcr\u00fctt\u00fcm.<\/p>\n\n\n\n

AbbVie, hastalar i\u00e7in yenilik\u00e7i ila\u00e7lar ke\u015ffetmeye ve geli\u015ftirmeye kendini adam\u0131\u015f ara\u015ft\u0131rma odakl\u0131 global bir biyofarma \u015firketi. 2013 y\u0131l\u0131ndan bu yana bilimsel uzmanl\u0131\u011f\u0131m\u0131z ve tecr\u00fcbemizle imm\u00fcnoloji, onkoloji, n\u00f6robilim, g\u00f6z sa\u011fl\u0131\u011f\u0131 ve medikal estetik gibi \u00f6ncelikli alanlarda d\u00fcnya \u00e7ap\u0131nda etki yaratan \u00e7\u00f6z\u00fcmler geli\u015ftiriyoruz. Molek\u00fcl ke\u015ffinden ila\u00e7 geli\u015ftirmeye kadar uzanan s\u00fcre\u00e7te hastalar\u0131 her zaman oda\u011f\u0131m\u0131za al\u0131yor; kar\u015f\u0131lanmam\u0131\u015f sa\u011fl\u0131k ihtiya\u00e7lar\u0131na \u00e7\u00f6z\u00fcm sunan yenilik\u00e7i tedavilere eri\u015fimi art\u0131rmay\u0131, bak\u0131m standartlar\u0131n\u0131 y\u00fckseltmeyi ve b\u00f6ylece hastalar\u0131n ya\u015fam kalitesini iyile\u015ftirmeyi toplumsal sorumlulu\u011fumuz olarak g\u00f6r\u00fcyoruz.<\/p>\n\n\n\n

Global bir biyofarma \u015firketi olarak yeni tedaviler geli\u015ftirmek \u00fczere Ar-Ge faaliyetleri sizin i\u00e7in ne anlam ifade ediyor? AbbVie\u2019nin \u00fclkemizde ila\u00e7 Ar-Ge\u2019sinin geli\u015fimine katk\u0131lar\u0131 neler? AbbVie y\u0131ll\u0131k cirosunun ne kadar\u0131n\u0131 Ar-Ge i\u00e7in ay\u0131r\u0131yor, global firmalar i\u00e7inde Ar-Ge ve klinik ara\u015ft\u0131rmalara yapt\u0131\u011f\u0131n\u0131z yat\u0131r\u0131mla bulundu\u011funuz konumu nas\u0131l de\u011ferlendirirsiniz?<\/strong><\/p>\n\n\n\n

AbbVie olarak odak tedavi alanlar\u0131nda d\u00fcnya standartlar\u0131nda ila\u00e7lar geli\u015ftiriyor, Ar-Ge\u2019ye yo\u011fun yat\u0131r\u0131m yap\u0131yoruz. Kurulu\u015fumuzdan bu yana 73 milyar ABD dolar\u0131n\u0131n \u00fczerinde kaynakla, 20 \u00fclkedeki ileri teknoloji merkezlerimizle inovasyonu destekliyoruz. Sadece 2024\u2019te gelirimizin %19\u2019unu, yakla\u015f\u0131k 10,8 milyar dolar\u0131n\u0131 Ar-Ge\u2019ye yat\u0131rd\u0131k. Portf\u00f6y\u00fcm\u00fczde 90\u2019a yak\u0131n molek\u00fcl ve cihaz bulunuyor. T\u00fcrkiye\u2019de ise Temmuz 2025 itibar\u0131yla imm\u00fcnoloji, onkoloji ve g\u00f6z sa\u011fl\u0131\u011f\u0131 alanlar\u0131nda 40 global klinik ara\u015ft\u0131rma y\u00fcr\u00fct\u00fcyoruz.<\/p>\n\n\n\n

Stratejik sat\u0131n almalarla bilimsel g\u00fcc\u00fcm\u00fcz\u00fc art\u0131r\u0131yoruz. 2025\u2019te Gubra ile yapt\u0131\u011f\u0131m\u0131z i\u015f birli\u011fiyle obezite tedavisinde yeni nesil bir amilin analo\u011fu geli\u015ftiriyoruz. Nimble Therapeutics’i sat\u0131n alarak otoimm\u00fcn hastal\u0131klar ve sedef hastal\u0131\u011f\u0131 i\u00e7in yeni oral peptid tedavilerini b\u00fcnyemize katt\u0131k. 2024\u2019te Aliada ve Cerevel Therapeutics’i sat\u0131n alarak n\u00f6rolojik hastal\u0131klara y\u00f6nelik g\u00fc\u00e7l\u00fc bir ara\u015ft\u0131rma portf\u00f6y\u00fcne sahip olduk. ImmunoGen\u2019in kat\u0131l\u0131m\u0131yla da onkoloji alan\u0131nda antikor-ila\u00e7 konjugatlar\u0131 geli\u015ftirerek \u00f6zellikle yumurtal\u0131k kanseri gibi zorlu hastal\u0131klara y\u00f6nelik \u00e7\u00f6z\u00fcmler sunma potansiyelimizi art\u0131rd\u0131k.<\/p>\n\n\n\n

AbbVie\u2019nin sosyal sorumlulu\u011fa bak\u0131\u015f a\u00e7\u0131s\u0131ndan bahseder misiniz? Toplum, hasta ve hekim odakl\u0131 hayata ge\u00e7irdi\u011finiz projelerinizi biraz anlat\u0131r m\u0131s\u0131n\u0131z?<\/strong><\/p>\n\n\n\n

AbbVie olarak insanlar\u0131n ya\u015famlar\u0131nda kal\u0131c\u0131 ve s\u00fcrd\u00fcr\u00fclebilir bir etki yaratmay\u0131 hedefliyor, topluma katk\u0131 sunmay\u0131 k\u00fclt\u00fcr\u00fcm\u00fcz\u00fcn temel bir par\u00e7as\u0131 olarak g\u00f6r\u00fcyoruz. 6 \u015eubat 2023\u2019te \u00fclkemizde ya\u015fanan b\u00fcy\u00fck deprem felaketinin ard\u0131ndan, sosyal sorumluluk oda\u011f\u0131m\u0131z\u0131 b\u00f6lgeden hi\u00e7 ay\u0131rmad\u0131k. AbbVie Vakf\u0131 arac\u0131l\u0131\u011f\u0131yla uluslararas\u0131 yard\u0131m kurulu\u015flar\u0131na 1 milyon dolar ba\u011f\u0131\u015fta bulunduk. Ayr\u0131ca TS\u00c7V i\u015f birli\u011fi ile Hatay\u2019daki depremden etkilenmi\u015f engelli \u00e7ocuklara 2.700\u2019\u00fcn \u00fczerinde fizyoterapi, \u00f6zel e\u011fitim ve psikolojik destek sunulmas\u0131na katk\u0131da bulunduk.<\/p>\n\n\n\n

2018 y\u0131l\u0131ndan bu yana \u00fclkemizde TS\u00c7V i\u015f birli\u011fiyle, spastisite ve otizm gibi n\u00f6rogeli\u015fimsel bozukluk riski ta\u015f\u0131yan 0-36 ay aras\u0131 bebeklerin erken d\u00f6nemde \u00f6zel e\u011fitim ile rehabilitasyon deste\u011fine ula\u015fmalar\u0131n\u0131 hedefleyen \u2018Kutup Y\u0131ld\u0131zlar\u0131\u2019 projesini y\u00fcr\u00fct\u00fcyoruz. \u2018Erken M\u00fcdahale Program\u0131\u2019 kapsam\u0131nda bug\u00fcne kadar 166 bebek ve ailesinin ya\u015fam\u0131na dokunarak sosyal hayata kat\u0131l\u0131mlar\u0131na katk\u0131 sunduk.<\/p>\n\n\n\n

Ayr\u0131ca AbbVie olarak her y\u0131l Haziran ay\u0131nda d\u00fcnya genelinde d\u00fczenledi\u011fimiz g\u00f6n\u00fcll\u00fcl\u00fck etkinli\u011fimiz \u2018Olas\u0131l\u0131klar Haftas\u0131\u2019 ile topluma de\u011fer katmaya devam ediyoruz. 2025 y\u0131l\u0131nda g\u00f6n\u00fcll\u00fcl\u00fck k\u00fclt\u00fcr\u00fcm\u00fcz\u00fc ya\u015fatarak hep birlikte anlaml\u0131 projelere imza att\u0131k. 80 g\u00f6n\u00fcll\u00fc \u00e7al\u0131\u015fma arkada\u015f\u0131m\u0131zla y\u00fcr\u00fctt\u00fc\u011f\u00fcm\u00fcz iki sosyal sorumluluk projesi, benim i\u00e7in de unutulmaz anlar bar\u0131nd\u0131r\u0131yor. 18 Haziran\u2019da Bilim Kahramanlar\u0131 Derne\u011fi\u2019yle Gaziantep\u2019te liseli gen\u00e7lerle bilim at\u00f6lyeleri d\u00fczenledik, onlar\u0131n g\u00f6zlerindeki merak ve umut hepimize ilham verdi. 26 Haziran\u2019da ise \u0130stanbul\u2019da TS\u00c7V ile serebral palsili \u00e7ocuklar i\u00e7in destek malzemeleri haz\u0131rlad\u0131k. Payla\u015fman\u0131n ve dayan\u0131\u015fman\u0131n g\u00fcc\u00fcn\u00fc derinden hissettik.<\/p>\n\n\n\n

Toplumla ba\u011f kuran bir kurum olma vizyonumuzla g\u00f6n\u00fcll\u00fcl\u00fck projelerine g\u00f6n\u00fclden ba\u011fl\u0131y\u0131z. Bu yakla\u015f\u0131m\u0131m\u0131z ile 2025\u2019te Great Place to Work Enstit\u00fcs\u00fc\u2019n\u00fcn \u2018Sosyal Sorumluluk ve G\u00f6n\u00fcll\u00fcl\u00fck\u2019 \u00f6zel \u00f6d\u00fcl\u00fcn\u00fc almaya hak kazand\u0131k.<\/p>\n\n\n\n

AbbVie neredeyse kuruldu\u011fu y\u0131ldan bu yana her sene en iyi i\u015fverenlerden biri oluyor.<\/strong> \u015eirketin genel m\u00fcd\u00fcr\u00fc olarak AbbVie\u2019de \u00e7al\u0131\u015fman\u0131n ayr\u0131cal\u0131klar\u0131n\u0131 sizden dinleyebilir miyiz? Nas\u0131l bir kurum k\u00fclt\u00fcr\u00fc var \u015firket i\u00e7erisinde?<\/strong><\/p>\n\n\n\n

AbbVie\u2019de en iyi fikirleri destekleyen kapsay\u0131c\u0131 bir k\u00fclt\u00fcre sahibiz. Hakkaniyet, e\u015fitlik, \u00e7e\u015fitlilik ve kapsay\u0131c\u0131l\u0131k yakla\u015f\u0131m\u0131m\u0131zla herkesin \u00f6zg\u00fcn kimli\u011fine de\u011fer veriyoruz. Cinsiyet e\u015fitli\u011fine verdi\u011fimiz \u00f6nemle, \u00e7al\u0131\u015fanlar\u0131m\u0131z\u0131n %47\u2019si, y\u00f6netim ekibimizin %61\u2019i ve liderlik rollerimizin %50\u2019si kad\u0131nlardan olu\u015fuyor. Bu dengeyi i\u015fe al\u0131mdan itibaren sistemli bi\u00e7imde g\u00f6zetiyor, kad\u0131n liderli\u011fini te\u015fvik ediyoruz. Ayr\u0131ca gen\u00e7 ku\u015faklar\u0131n sesine kulak veriyor; Fresh, Xperience, FreshMED ve FutureMED gibi gen\u00e7 yetenek programlar\u0131m\u0131zla onlar\u0131n geli\u015fimini destekliyoruz. 30 ya\u015f alt\u0131 \u00e7al\u0131\u015fanlar\u0131m\u0131zdan olu\u015fan Gen\u00e7 Dan\u0131\u015fma Kurulumuz sayesinde gen\u00e7 bak\u0131\u015f a\u00e7\u0131s\u0131n\u0131 stratejimize ve k\u00fclt\u00fcr\u00fcm\u00fcze entegre ediyoruz. Bu yakla\u015f\u0131mlar\u0131m\u0131z ile 2025 y\u0131l\u0131nda Great Place to Work Enstit\u00fcs\u00fc taraf\u0131ndan \u2018Best Workplaces for Young Millennials\u2019 \u00f6d\u00fcl\u00fcne l\u00e2y\u0131k g\u00f6r\u00fcld\u00fck.<\/p>\n\n\n\n

AbbVie olarak kapsay\u0131c\u0131l\u0131\u011f\u0131 sadece s\u00f6ylemde de\u011fil, ya\u015fam\u0131n her alan\u0131nda hayata ge\u00e7iriyoruz. Partner Sa\u011fl\u0131k Sigortas\u0131, \u00f6zel izin uygulamalar\u0131m\u0131z, Vitality \u00e7al\u0131\u015fan destek program\u0131, yaz d\u00f6neminde geni\u015fletilmi\u015f esnek ve uzaktan \u00e7al\u0131\u015fma imkan\u0131 gibi haklarla \u00e7al\u0131\u015fanlar\u0131m\u0131z\u0131 destekliyoruz.<\/p>\n\n\n\n

Bu insan odakl\u0131 yakla\u015f\u0131mlar\u0131m\u0131z sayesinde 2025 y\u0131l\u0131nda GPTW taraf\u0131ndan d\u00fczenlenen \u2018T\u00fcrkiye\u2019nin En \u0130yi \u0130\u015fverenleri\u2019 ara\u015ft\u0131rmas\u0131nda birinci se\u00e7ilerek bu unvan\u0131 11. kez kazand\u0131k. Bug\u00fcne kadar aralar\u0131nda \u2018Kad\u0131nlar i\u00e7in En \u0130yi \u0130\u015fveren\u2019, \u2018Ya\u015fam Boyu \u00d6\u011frenme\u2019, \u2018Sa\u011fl\u0131k Hizmetleri ve Farma\u2019n\u0131n En \u0130yi \u0130\u015fvereni\u2019, \u2018Innovation by All\u2019 ve \u2018Diversity\u2019 \u00f6zel \u00f6d\u00fcllerinin de oldu\u011fu toplam 40 \u00f6d\u00fcl, \u00e7al\u0131\u015fanlar\u0131m\u0131za ve de\u011ferlerimize verdi\u011fimiz \u00f6nemin bir yans\u0131mas\u0131.<\/p>\n","protected":false},"excerpt":{"rendered":"

AbbVie T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Barlas D\u00f6ner ile \u015firketin odakland\u0131\u011f\u0131 tedavi alanlar\u0131ndan Ar-Ge \u00e7al\u0131\u015fmalar\u0131na, sosyal sorumluluk anlay\u0131\u015f\u0131ndan kurum k\u00fclt\u00fcr\u00fc ve \u0130K stratejilerine kadar uzanan kapsaml\u0131 bir s\u00f6yle\u015fi ger\u00e7ekle\u015ftirdik.<\/p>\n","protected":false},"author":1,"featured_media":4470,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,2],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4468"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4468"}],"version-history":[{"count":2,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4468\/revisions"}],"predecessor-version":[{"id":4472,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4468\/revisions\/4472"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4470"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}